[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nodular-basal-cell-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nodular-basal-cell-carcinoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644537","phase-1-study-of-intralesional-fld-103-in-subjects-with-basal-cell-carcinoma-bcc-100644537",false,"NCT07670858","Study of Intralesional FLD-103 in Subjects With Basal Cell Carcinoma (BCC)","A Phase 1, First-In-Human, Single and Multiple Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Efficacy of Intralesional FLD-103 in Subjects With Basal Cell Carcinoma (BCC).","Inclusion Criteria:\n\n* You are between 18 and 85 years old.\n* You are willing to attend all study visits and follow the study procedures.\n* You have been diagnosed with at least one nodular basal cell carcinoma (a type of skin cancer) that has never been treated and suitable for treatment and final excision by the Investigator.\n* You are willing to avoid certain medications during the study as instructed by the study doctor.\n* You are not currently participating in another clinical study.\n* If you are a woman who could become pregnant, you must:\n* Have a negative pregnancy test at the start of the study.\n* Use effective birth control during the study and for 90 days after your last dose.\n* Not breastfeed during the study and for 90 days after your last dose.\n* If you are a man, you must use a condom during the study and for 90 days after your last dose if you have sex with a partner who could become pregnant.\n\nExclusion Criteria:\n\n* You are currently breastfeeding.\n* You have a known allergy or sensitivity to any ingredient in the study drug or to red tattoo ink.\n* Your skin lesion is located in a high-risk area, such as near the eyes, nose, ears, lips, scalp, or on the hands or fingers.\n* Your skin lesion needs to be removed urgently.\n* Your basal cell carcinoma has spread to other parts of the body.\n* You have received radiation therapy directly on or near the skin lesion being treated in this study.\n* You have received phototherapy (such as Ultraviolet A or B light therapy) in the past 4 weeks or are expected to receive it during the study.\n* You have been diagnosed with a liver or kidney disease that the study doctor considers significant.\n* You are immunocompromised or have an active infection such as Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C or active Tuberculosis.\n* You have or had another cancer in the past 5 years\n* You have a skin condition associated with an increased risk of developing skin cancers (such as Xeroderma Pigmentosum).\n* You have uncontrolled high blood pressure or a heart rhythm problem.\n* You have had significant alcohol or drug use issues in the past 6 months, or have a mental health condition that the study doctor believes may affect your ability to participate safely.\n* You are currently taking certain medications that are not allowed during the study\n* You are an employee or family member of an employee at the study site or of the study doctor.","ALL","18 Years","85 Years",{"count":20,"type":21},48,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The goal of this clinical trial is to determine safety, tolerability, pharmacokinetics, preliminary efficacy, and Maximum Tolerable Dose (MTD), of intralesional FLD-103 when administered to subjects with Basal Cell Carcinoma (BCC). The main questions it aims to answer are:\n\n* Is FLD-103 safe and well tolerated?\n* What is a safe dose of FLD-103 for future studies?\n* How much FLD-103 enters the bloodstream and how long does it take to be cleared from the body?\n* Does FLD-103 reduce the size of the tumor?\n\nParticipants will:\n\n* Receive either a Single Ascending Dose (SAD) of FLD-103 or Multiple Ascending Doses (MAD) of FLD-103 once weekly for four (4) weeks.\n* Visit the clinic a day after receiving a dose and once weekly for four (4) weeks after that for checkups and tests.",[27],"Nodular Basal Cell Carcinoma",[29,30],"nBCC","Intralesional","RECRUITING","2026-06-25",{"date":34,"type":35},"2026-06-29","ACTUAL",{"date":37,"type":35},"2024-10-30",{"date":39,"type":21},"2027-03",{"name":41,"class":42},"Feldan Therapeutics","INDUSTRY",9,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100622473","high-intensity-focused-ultrasound-vs-cryotherapy-in-the-treatment-of-basal-cell-carcinomas-and-bowens-disease-in-adults-100622473","NCT07384078","High Intensity Focused Ultrasound vs. Cryotherapy in the Treatment of Basal Cell Carcinomas and Bowen's Disease in Adults","HIFU vs. CRYO - High Intensity Focused Ultrasound vs. Cryotherapy in the Treatment of Basal Cell Carcinomas and Bowen's Disease - a Randomized Controlled Trial","HIFUvsCRYO","Inclusion Criteria:\n\n* age 18 years or older at the time of informed consent\n* ability to give informed consent and comply with the treatment protocol and follow-up plan\n* study lesion located between neck and knees\n* one of following histologically confirmed diagnosis: Superficial BCC with maximum diameter of 2.0 cm \u002F Nodular BCC with max. diameter of 1.5 cm \u002F BD with max. diameter of 2.0 cm\n\nExclusion Criteria:\n\n* Study lesion location in face, head, genitals, hands, or below the knee\n* Clinical\u002Fdermoscopical\u002Fhistological feature for high-risk\u002Faggressive BCC\n* Clinical\u002Fhistological sign for hypertrophic BD\n* Clinical\u002Fdermoscopical\u002Fhistological feature for Squamous cell carcinoma\n* Gorlin Golz syndrome\n* Pregnancy or breastfeeding",{"count":53,"type":21},294,[55],"NA","This prospective, randomized, controlled, and single-blinded non-inferiority clinical trial compare the efficacy and tolerability of high intensity focused ultrasound (HIFU) to standard cryotherapy in the treatment of low-risk basal cell carcinomas (BCCs) and Bowen's disease (BD) in adults. The main questions it aims to answer are:\n\n* Is HIFU an efficient treatment option for BCCs and BD?\n* What medical problems do participants get after HIFU?\n\nResearchers will compare HIFU to standard cryotherapy with liquid nitrogen to see if the ultrasound works to treat these local and low-risk non-melanosytic skin cancers.\n\nParticipants will:\n\n* Be treated either with HIFU (intervention) or cryotherapy (control).\n* Visit the clinic 4 weeks, 1-, 3- and 5 years after the treatment for check-ups, tests and survey questions.",[58,27,59,60,61],"Superficial Basal Cell Carcinoma","Bowen's Disease","BCC","BD",[63,64,65,66,67,68,69,70,71],"HIFU","cryo","cryotherapy","high intensity focused ultrasound","basal cell carcinoma","Bowen's disease","superficial basal cell carcinoma","nodular basal cell carcinoma","non-surgical treatment","NOT_YET_RECRUITING","2026-01-26",{"date":75,"type":35},"2026-02-03",{"date":77,"type":21},"2026-04-01",{"date":79,"type":21},"2032-12-31",{"name":81,"class":82},"Jussi Salonen","OTHER",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":5},"100451381","phase-1-a-study-to-evaluate-the-safety-and-efficacy-of-escharex-ex-02-in-the-treatment-of-basal-cell-carcinoma-100451381","NCT05157763","A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma","An Open-Label Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma","Inclusion Criteria:\n\nInclusion Criteria- Patient level\n\n1. Male or female greater than age 18,\n2. Patients with one primary superficial or nodular basal cell carcinoma lesion (Histologically confirmed BCC) located on the trunk or upper extremities (not including the hands), with well-defined borders and no previous radiation therapy.\n3. Lesion is present for no longer than 4 years.\n4. Lesion with a diameter of 5-10mm,\n5. Patient and\u002For legally authorized representative (LAR) understands the nature of the procedure, is able and willing to adhere to the protocol regimen, and able to provide a written informed consent prior to any study procedure.\n\nExclusion Criteria:\n\nExclusion Criteria- Patient level\n\n1. Evidence of Gorlin syndrome, neoplastic diseases (except actinic lesions), metastatic tumor or tumor with high probability of metastatic spread,\n2. Other malignant cancers (non BCC) of the skin at the lesion's site,\n3. Morphea-type basal cell carcinoma (MBCC) at the lesion's site (per biopsy report),\n4. Any signs of infection at the lesion site including purulent discharge, tissue abscess, erysipelas, cellulitis, etc.,\n5. Patients with any dermatological disease in the target lesion site or surrounding area (not including chronic actinic damage in the surrounding area),\n6. History of allergy or atopic disease or a known sensitivity to pineapples, papaya, bromelain or papain, as well as known sensitivity to latex proteins (known as latex-fruit syndrome), bee venom or olive tree pollen,\n7. Patients undergoing renal or peritoneal dialysis,\n8. Any condition that would preclude safe participation in the study, e.g. evidence of significant or unstable cardiovascular, pulmonary, liver, hematological, immunological, or any immediate life threatening condition,\n9. Concurrent acute injury or disease that might compromise the patient's welfare or the participation in the study,\n10. Current (within last 12 months) severe alcohol or drug use disorder\n11. Pregnant women (positive blood or urine pregnancy test) or nursing mothers,\n12. Exposure to investigational intervention within 4 weeks prior to enrolment, or anticipated participation in another investigational drug trial or other intervention trial, while enrolled in the study.",{"count":92,"type":21},32,[24,94],"PHASE2","This study will be a multicenter, prospective, open label, one-arm study intended to assess the Safety and Efficacy of EscharEx (EX-02) in the treatment of Basal Cell Carcinoma.\n\nIn patients with one primary superficial or nodular basal cell carcinoma lesion with a diameter of 5-10mm (Histologically confirmed BCC) located on the trunk or upper extremities (not including the hands), with well-defined borders and no previous radiation therapy.",[58,27],"2021-12-01",{"date":99,"type":35},"2021-12-15",{"date":101,"type":35},"2021-06-30",{"date":103,"type":21},"2022-06",{"name":105,"class":42},"MediWound Ltd"]